Dataset Information

RNA-sequencing transcriptional profile of human hearts [HumanHeartFailure]

ABSTRACT: Organ fibroblasts are essential components of homeostatic and diseased tissues, as they participate in sensing the microenvironment and communicating with other resident cells. They are also involved in pathological remodeling and fibrosis, caused by excessive deposition of connective tissue after injury, which impairs organ function. It is estimated that 45% of deaths in developed countries are linked to chronic fibrosis, yet current drugs on the market are both inefficient and non-specific to this condition. We have previously shown that cardiac fibroblasts display a unique cardiogenic identity, important for cardiac pathological remodeling. To determine whether fibroblasts from other organ systems display a molecular signature unique to their organ of origin, we characterized fibroblasts isolated from the adult mouse skin, lung, kidney, gonad and liver, and documented a molecular positional and organ signature that is likely a remnant from embryonic development. This information opens novel opportunities for the treatment of fibrotic diseases in a more precise, organ-specific manner.

ORGANISM(S): Homo sapiens

PROVIDER: GSE175764 | GEO | 2022/04/06

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Background: Organ fibrosis due to excessive production of extracellular matrix (ECM) by resident fibroblasts is estimated to contribute to >45% of deaths in the Western world, including those due to cardiovascular diseases such as heart failure (HF). Here, we screened for small molecule inhibitors with a common ability to suppress activation of fibroblasts across organ systems. Methods: High content imaging of cultured cardiac, pulmonary and renal fibroblasts was employed to identify non-toxic compounds that blocked induction of markers of activation in response to the profibrotic stimulus, TGF-β. SW033291, which inhibits the eicosanoid-degrading enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), was chosen for follow-up studies with cultured adult rat ventricular fibroblasts (ARVFs) and human cardiac fibroblasts (CFs), and for evaluation in mouse models of cardiac fibrosis and diastolic dysfunction. Additional mechanistic studies were performed with CFs treated with exogenous eicosanoids. Results: Nine compounds, including SW033291, shared a common ability to suppress TGF-β-mediated activation of cardiac, pulmonary and renal fibroblasts. SW033291 dose-dependently inhibited TGF-β-induced expression of activation markers (e.g. α-smooth muscle actin and periostin) in ARVFs and normal human CFs, and reduced contractile capacity of the cells. Remarkably, the 15-PGDH inhibitor also reversed constitutive activation of fibroblasts obtained from explanted hearts from patients with HF. SW033291 blocked cardiac fibrosis induced by angiotensin II (Ang II) infusion and ameliorated diastolic dysfunction in an alternative model of systemic hypertension driven by combined uninephrectomy (UNX) and deoxycorticosterone acetate (DOCA) administration. Mechanistically, SW033291-mediated stimulation of ERK1/2 mitogen-activated protein kinase signaling was required for SW033291 to block CF activation. Of the 12 exogenous eicosanoids that were tested, only 12-hydroxyeicosatetraenoic acid (12[S]-HETE), which signals through the G protein-coupled receptor (GPCR), GPR31, recapitulated the suppressive effects of SW033291 on CF activation. Conclusions: Inhibition of degradation of eicosanoids, arachidonic acid-derived fatty acids that signal through GPCRs, is a potential therapeutic strategy for suppression of pathological organ fibrosis. In the heart, we propose that 15-PGDH inhibition triggers CF-derived autocrine/paracrine signaling by eicosanoids, including 12(S)-HETE, to stimulate ERK1/2 and block conversion of fibroblasts into activated cells that secrete excessive amounts of ECM and contribute of HF pathogenesis.

Dataset Information

RNA-sequencing transcriptional profile of human hearts [HumanHeartFailure]

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure